Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Reduce” from Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned a consensus rating of “Reduce” from the ten research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have issued a hold rating on the company.

BAYRY has been the subject of several recent research reports. The Goldman Sachs Group started coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They set a “neutral” rating for the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY opened at $6.90 on Friday. Bayer Aktiengesellschaft has a 1-year low of $6.89 and a 1-year high of $14.70. The firm’s 50-day moving average price is $7.47 and its 200-day moving average price is $7.85. The company has a quick ratio of 0.87, a current ratio of 1.31 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 14th. The company reported $0.77 earnings per share for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 17.57% and a negative net margin of 6.70%. The company had revenue of $14.95 billion for the quarter. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.36 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.